Brattea Raises ￥100 Million in Extended Series B Round

(VCBeat) Apr. 05, 2021 -- Shanghai Meili Weiye Medical Technology Co., Ltd. ("Brattea"), a domestic leader in neuro-radiofrequency ablation, announced that it had obtained a Series B+ financing of over 100 million yuan, led by Kuanping Capital. New investors include Hengxu Capital, Pudong Science & Technology Co., and Brosmed. Prior round investors include Northern Light Venture Capital, BioTrack Capital, and Sherpa Healthcare Partners.

This round of financing is the largest investment event in the renal denervation (RDN) sector in China so far.

Founded in 2013, Brattea specializes in the research, development and commercialization of RDN products. The company owns a number of world-leading patented technologies with independent intellectual property rights in this field. It also has close cooperation with well-known experts, universities and hospitals in China. Brattea has successfully developed a percutaneous intravascular radiofrequency nerve ablation platform for chronic disease treatment and management. It has taken a leading position in the field of minimally invasive treatment of hypertension both at home and abroad, and has made significant progress in multiple promising indications including cancer pain and diabetes.

Brattea plans to use the funds to accelerate clinical trials, expand its clinical and technical teams, consolidate its leading position in RDN, and build itself into a platform company based on neuro-radiofrequency ablation technology.

The RDN sector is one of the few subdivision tracks in the medical device industry where the leading domestic enterprises and the global leaders are still at the same starting line. Both in terms of product performance and clinical effect, the original products of Brattea have shown many advantages over the SPYRAL series of Medtronic's products, and are expected to become the "Best in Class" products worldwide in the future.

Founded in 2016, Kuanping Capital is a healthcare dedicated private equity fund with offices in Beijing and Shanghai. They focus on attractive areas including Medtech, Healthcare Service, Biotech, and Digital Health. "Buy and Build" is Kuanping Capital's core philosophy. In addition to capital support, they work closely with management to integrate resources, improve operation efficiency and embrace new technology.

Established on July 16, 2019, Hengxu Capital is SAIC Capital's parent fund management platform. While relying on the resources of SAIC, Hengxu Capital invests in strategic emerging industries such as advanced manufacturing, cutting-edge technology, big health, and big consumption. With the capital, it contributes to the development of SAIC's innovative industry chain and the improvement of SAIC's ecosystem. The current AUM of Heng Xu Capital is RMB 6.9 billion.